NASDAQ:VRNA Verona Pharma (VRNA) Stock Price, News & Analysis → Perma Bull: This is what terrifies me about AI (From InvestorPlace) (Ad) Free VRNA Stock Alerts $15.04 -0.65 (-4.14%) (As of 11:40 AM ET) Add Compare Share Share Today's Range$15.01▼$15.7050-Day Range$15.22▼$18.1952-Week Range$11.83▼$23.81Volume184,196 shsAverage Volume489,175 shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/APrice Target$33.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Verona Pharma alerts: Email Address Verona Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside123.0% Upside$33.60 Price TargetShort InterestBearish7.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 5 Articles This WeekInsider TradingSelling Shares$71,046 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.32) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.18 out of 5 starsMedical Sector524th out of 908 stocksPharmaceutical Preparations Industry242nd out of 424 stocks 3.5 Analyst's Opinion Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerona Pharma has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.51% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Verona Pharma has recently decreased by 7.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRNA. Previous Next 1.9 News and Social Media Coverage News SentimentVerona Pharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Verona Pharma this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,046.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verona Pharma are expected to grow in the coming year, from ($1.32) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -21.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -21.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Lear CapitalDollar CancelledDon’t wait to protect your hard-earned savings. Top economists and billionaires are predicting that the dollar could collapse before the end of 2024.Get informed and prepare now before it’s too late. About Verona Pharma Stock (NASDAQ:VRNA)Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More VRNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRNA Stock News HeadlinesMay 5, 2024 | insidertrades.comKathleen A. Rickard Sells 36,248 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 2, 2024 | americanbankingnews.comVerona Pharma (VRNA) Set to Announce Quarterly Earnings on ThursdayMay 6, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 2, 2024 | globenewswire.comVerona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024April 25, 2024 | investing.comVerona Pharma shares target raised on COPD launch outlookApril 25, 2024 | globenewswire.comVerona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateMarch 16, 2024 | finance.yahoo.comVRNA Apr 2024 17.500 callMarch 16, 2024 | finance.yahoo.comVRNA Apr 2024 15.000 callMay 6, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 4, 2024 | globenewswire.comAndrew Fisher Joins Verona Pharma as General CounselMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D PipelineMarch 1, 2024 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | fool.com3 Healthcare Stocks That Have Outperformed Nvidia Since 2022February 29, 2024 | seekingalpha.comVerona Pharma plc 2023 Q4 - Results - Earnings Call PresentationFebruary 29, 2024 | finanznachrichten.deVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 29, 2024 | finance.yahoo.comVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | markets.businessinsider.comVerona Pharma earnings preview: what to expectFebruary 25, 2024 | finance.yahoo.comWhen Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?February 25, 2024 | wsj.comVerona Pharma PLC ADRFebruary 17, 2024 | finance.yahoo.comVRNA Mar 2024 15.000 putFebruary 17, 2024 | finance.yahoo.comVRNA Jun 2024 30.000 callFebruary 15, 2024 | seekingalpha.comVerona Pharma: A Few Points From The Bull And Bear CaseFebruary 15, 2024 | finance.yahoo.comVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateFebruary 15, 2024 | globenewswire.comVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateJanuary 23, 2024 | investing.comVerona Pharma PLC ADR (VRNA)January 19, 2024 | seekingalpha.comVerona Pharma: Upcoming PDUFA, Expired Patent, Strong DataSee More Headlines Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/06/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VRNA CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees79Year FoundedN/APrice Target and Rating Average Stock Price Target$33.60 High Stock Price Target$36.00 Low Stock Price Target$32.00 Potential Upside/Downside+123.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax Margin-10,946.07% Return on Equity-20.47% Return on Assets-17.72% Debt Debt-to-Equity Ratio0.20 Current Ratio33.33 Quick Ratio33.33 Sales & Book Value Annual Sales$460,000.00 Price / Sales2,647.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book4.86Miscellaneous Outstanding Shares80,820,000Free Float76,937,000Market Cap$1.22 billion OptionableOptionable Beta0.43 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. David S. Zaccardelli Pharm.D. (Age 60)President, CEO & Executive Director Comp: $1.27MMr. Mark W. Hahn (Age 61)Chief Financial Officer Comp: $858.29kDr. Kathleen A. Rickard M.D. (Age 66)Chief Medical Officer Comp: $650.83kMr. Andrew Fisher (Age 54)General Counsel Ms. Victoria StewartDirector of CommunicationsMr. Matthew CasbonVP of Sales, Marketing & TrainingMs. Ostra JewellSenior Vice President of Human ResourcesDr. Tara Rheault M.P.H. (Age 47)Ph.D., Chief Development Officer Mr. Christopher MartinChief Commercial OfficerMs. Caroline DiazSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDGemini TherapeuticsNASDAQ:GMTXPacira BioSciencesNASDAQ:PCRXIronwood PharmaceuticalsNASDAQ:IRWDCollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsKathleen A RickardSold 36,248 sharesTotal: $71,046.08 ($1.96/share)Jennison Associates LLCBought 8,448 shares on 5/2/2024Ownership: 1.972%Capstone Investment Advisors LLCBought 25,616 shares on 5/1/2024Ownership: 0.032%BNP Paribas Financial MarketsBought 21,384 shares on 5/1/2024Ownership: 0.029%Matisse CapitalBought 19,400 shares on 5/1/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions VRNA Stock Analysis - Frequently Asked Questions Should I buy or sell Verona Pharma stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares. View VRNA analyst ratings or view top-rated stocks. What is Verona Pharma's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month target prices for Verona Pharma's stock. Their VRNA share price targets range from $32.00 to $36.00. On average, they expect the company's share price to reach $33.60 in the next twelve months. This suggests a possible upside of 123.0% from the stock's current price. View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts. How have VRNA shares performed in 2024? Verona Pharma's stock was trading at $19.88 at the start of the year. Since then, VRNA stock has decreased by 24.2% and is now trading at $15.07. View the best growth stocks for 2024 here. When is Verona Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VRNA earnings forecast. How can I listen to Verona Pharma's earnings call? Verona Pharma will be holding an earnings conference call on Thursday, May 9th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) released its quarterly earnings results on Thursday, February, 29th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. What ETF holds Verona Pharma's stock? ALPS Medical Breakthroughs ETF holds 57,444 shares of VRNA stock, representing 0.85% of its portfolio. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT). When did Verona Pharma IPO? Verona Pharma (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma's major shareholders? Verona Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Vivo Capital LLC (4.47%), Jennison Associates LLC (1.97%), Rice Hall James & Associates LLC (0.84%), Hennion & Walsh Asset Management Inc. (0.08%), PFG Investments LLC (0.03%) and Capstone Investment Advisors LLC (0.03%). Insiders that own company stock include Claire Poll, David R Ebsworth, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Martin Edwards and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRNA) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsElon to Transform U.S. Economy? Porter & CompanyDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold“Crash Insurance” For Your RetirementUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
